About this trial
This is a Phase II, single arm, multi-centre, prospective clinical trial evaluating next generation Stereotactic Ablative Radiotherapy (SABR) for low, intermediate, and eligible high-risk prostate cancer. Eligible patients will receive next generation prostate SABR incorporating toxicity reduction strategies: urethral/trigone sparing, rectal hydrogel spacer, and neurovascular bundle preservation . Treatment will prioritise the dominant intraprostatic lesion (DIL) while sparing surrounding organs at risk (OARs).
Patient Profile
low- medium- and eligible high risk prostate cancer patients, with biopsy confirmed prostate adenocarcinoma
Where’s this trial being run?
Bon Secours Radiotherapy Cork in Partnership with UPMC Hillman Cancer Centre
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | INSPIRE: INnovative SABR for Prostate cancer all IREland |
|---|---|
| Number: | 24-72 |
| Full Title: | INSPIRE: INnovative SABR for Prostate cancer all IREland |
| Principal Investigator: | Prof. Brian O'Neill (SLRON), Prof. Suneil Jain (QUB) |
|---|---|
| Type: | In-House |
| Sponsor: | Cancer Trials Ireland |
| Recruitment Started: |
Global: Ireland: April 2026 |
| Global Recruitment Target: | |
|---|---|
| Ireland Recruitment Target: | 136 |